Storia in 2 fonti

Corneal endothelial cell therapy earns regenerative medicine advanced therapy designation

The FDA granted regenerative medicine advanced therapy designation to EO2002 for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release from Emmecell.

Raccontata da

healio.com

morningstar.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo1 mese fa

Corneal endothelial cell therapy earns regenerative medicine advanced therapy designation

originale

morningstar.com1 mese fa

Emmecell Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EO2002 for the Treatment…

Emmecell Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EO2002 for the Treatment of Corneal Endothelial DiseaseRMAT designation recognizes the potential of EO2002 to address a serious…

Leggi questa versione →

Corneal endothelial cell therapy earns regenerative medicine advanced therapy designation

Emmecell Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EO2002 for the Treatment…

Timeline cronologica

Corneal endothelial cell therapy earns regenerative medicine advanced therapy designation

Emmecell Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EO2002 for the Treatment of Corneal Endothelial Disease